GPP
PTCT icon

Great Point Partners’s PTC Therapeutics PTCT Stock Holding History

Great Point Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-200,000
Closed -$5.41M – 43
2018
Q1 		$5.41M Buy
+200,000
New +$5.07M 0.8% 26
2017
Q4 		– Sell
-460,000
Closed -$9.21M – 44
2017
Q3 		$9.21M Buy
460,000
+200,000
+77% +$3.92M 1.79% 21
2017
Q2 		$4.77M Buy
+260,000
New +$3.5M 0.85% 27

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Great Point Partners's PTCT Position: Q4 2023 in Review

Great Point Partners sold out of PTC Therapeutics (PTCT) in Q4 2023, closing a stake of 500,000 shares — an estimated $11.2M sold.

Great Point Partners first reported a position in PTCT in Q1 2017 and held it in 16 quarters. The position peaked at $88.8M in Q2 2019. 172 funds tracked by Wall St. Rank hold PTCT as of Q4 2023.

  • Great Point Partners reported no remaining PTC Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Great Point Partners sold 500,000 PTC Therapeutics shares in Q4 2023, an estimated $11.2M.
  • Great Point Partners first reported a position in PTC Therapeutics in Q1 2017 and held it in 16 quarters.
  • Great Point Partners's PTC Therapeutics position peaked at $88.8M in Q2 2019.
  • 172 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2023.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.